相关实验视频
Updated: Jan 28, 2026

06:47
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
12.4K
穆瓦拉普林:一种用于有针对性减少血脂蛋白的新型口服疗法 (a)
Monica Botros1, Michelle Tiji2, Richard Lange3
1Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
Cardiovascular & hematological disorders drug targets
|January 27, 2026
概括
口服药物穆瓦拉普林在降低高脂蛋白[Lp]水平方面表现有前途,这是一个关键的心血管风险因素. 早期试验表明显著的Lp(a) 减少没有重大安全问题,提供了一个新的治疗途径.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 脂质代谢 脂质代谢是什么
背景情况:
- 血脂蛋白[Lp]水平升高 (>50 mg/dL) 是心血管疾病 (如心力衰竭,动脉样硬化和大动脉狭窄) 的独立危险因素.
- Lp (a) 通过包括血管炎症,血栓形成和化在内的益动原性机制促进心血管风险.
- 目前针对Lp(a) 的治疗策略有限,有几种药物正在评估中.
研究的目的:
- 审查穆瓦拉普林的疗效,安全性和耐受性,这是第一个旨在降低血Lp (a) 水平的口服药物.
- 为了将穆瓦拉普林的治疗特征与其他新兴的Lp (a) 降低剂进行比较.
- 评估穆瓦拉普林作为一种新型治疗方法的潜力,用于管理与升高Lp相关的心血管风险.
主要方法:
- 使用PubMed数据库 (2020-2025) 进行了系统的文献搜索,关键词是:muvalaplin,脂蛋白和心血管.
- 包括的研究包括原始研究,临床试验和评论文章.
- 来自穆瓦拉普林I期和II期临床试验的数据被评估为Lp (a) 减少,安全性和耐受性.
主要成果:
- 一期试验表明,14天每天服用muvalaplin可将Lp(a) 水平降低高达65%.
- 第二阶段试验显示,每天服用慕瓦拉普林12周,可达到高达86%的Lp (a) 减少,没有显著的安全性或耐受性问题.
- 穆瓦拉普林在注射部位没有引起与皮肤相关的不良事件,这使其与其他Lp (a) 降低疗法有所区别.
结论:
- 穆瓦拉普林是一种口服小分子抑制剂,在显著降低血Lp (a) 水平方面显示出有希望的疗效.
- 在早期的临床试验中,该药物似乎被很好地容忍,这表明与注射药物相比,它具有有利的安全性.
- 进一步的III期试验至关重要,以证实长期的安全性,并证明用muvalaplin减少Lp (a) 是否会导致心血管事件的减少.
相关概念视频
Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
Oxidation-Reduction Reactions
75.5K
Oxidation–Reduction Reactions
75.5K
Oral Cavity
3.1K
The oral cavity, or the mouth, is a complex structure in humans that plays a vital role in our day-to-day lives. Its role is not only in chewing and swallowing food; it also plays a role in speech and facial expressions.
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
3.1K
Gene Therapy
27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Block Diagram Reduction
552
The process of deriving the transfer function of a control system often involves reducing its block diagram to a single block. This simplification can be achieved through a series of strategic operations, including relocating branch points and comparators. These operations preserve the overall function of the system while allowing for easier manipulation and combination of blocks.
The first step in this process is the identification and relocation of a branch point. A branch point, where a...
The first step in this process is the identification and relocation of a branch point. A branch point, where a...
552
Oxymercuration-Reduction of Alkenes
9.3K
Oxymercuration–reduction of alkenes is one of the major reactions converting alkenes to alcohols. It involves the hydration of alkenes with mercuric acetate in a mixture of tetrahydrofuran and water, forming an organomercury adduct. This is followed by a demercuration step in which the adduct is reduced to an alcohol using sodium borohydride.
9.3K

